Turning Point Therapeutics Inc. (TPTX)’s Financial Results Comparing With XBiotech Inc. (NASDAQ:XBIT)

Turning Point Therapeutics Inc. (NASDAQ:TPTX) and XBiotech Inc. (NASDAQ:XBIT), both competing one another are Biotechnology companies. We will contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Turning Point Therapeutics Inc. N/A 0.00 33.60M -7.31 0.00
XBiotech Inc. N/A 0.00 22.93M -0.64 0.00

Table 1 highlights Turning Point Therapeutics Inc. and XBiotech Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Turning Point Therapeutics Inc. 0.00% 0% 0%
XBiotech Inc. 0.00% -51.9% -48.9%

Insider & Institutional Ownership

Turning Point Therapeutics Inc. and XBiotech Inc. has shares held by institutional investors as follows: 0% and 13.5%. Competitively, XBiotech Inc. has 37.8% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Turning Point Therapeutics Inc. -7.93% 0% 0% 0% 0% 7.61%
XBiotech Inc. -1.05% 4.56% 14.22% 144.16% 114.12% 85.04%

For the past year Turning Point Therapeutics Inc. was less bullish than XBiotech Inc.

Summary

On 4 of the 6 factors XBiotech Inc. beats Turning Point Therapeutics Inc.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.